Biodol

Executive Summary

Biodol Therapeutics is a French biopharmaceutical company founded in 2015, advancing first-in-class small molecule therapeutics targeting the FLT3 receptor for chronic neuropathic pain. Its platform also aims to enhance opioid efficacy and reduce tolerance, addressing a critical unmet need in pain management. Currently in Phase 1 development, the company is privately held with no disclosed funding or valuation. While early-stage, its differentiated mechanism targeting FLT3 could offer a novel approach to neuropathic pain, a large and growing market. However, the company faces significant clinical and regulatory risks typical of Phase 1 biotechs. Given the early stage and lack of public data, conviction is moderate. Success hinges on demonstrating safety and preliminary efficacy in ongoing trials.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 safety and PK/PD data readout25% success
• Q4 2026Potential partnership or licensing deal15% success
• Q2 2026Grant or non-dilutive funding announcement30% success